Simvastatin and atorvastatin facilitates amyloid β-protein degradation in extracellular spaces by increasing neprilysin secretion from astrocytes through activation of MAPK/Erk1/2 pathways

Glia ◽  
2016 ◽  
pp. n/a-n/a ◽  
Author(s):  
Naoki Yamamoto ◽  
Yoko Fujii ◽  
Rika Kasahara ◽  
Mamoru Tanida ◽  
Kentaro Ohora ◽  
...  
2003 ◽  
Vol 278 (39) ◽  
pp. 37314-37320 ◽  
Author(s):  
Malcolm A. Leissring ◽  
Alice Lu ◽  
Margaret M. Condron ◽  
David B. Teplow ◽  
Ross L. Stein ◽  
...  

2013 ◽  
Vol 545 ◽  
pp. 54-58 ◽  
Author(s):  
Naoki Yamamoto ◽  
Hajime Arima ◽  
Kaori Naruse ◽  
Rika Kasahara ◽  
Hideo Taniura ◽  
...  

2021 ◽  
Vol 7 (13) ◽  
pp. eabc9750
Author(s):  
Nozomu Nagashima ◽  
Shuta Ozawa ◽  
Masahiro Furuta ◽  
Miku Oi ◽  
Yukiko Hori ◽  
...  

Protein degradation induced by small molecules by recruiting endogenous protein degradation systems, such as ubiquitin-proteasome systems, to disease-related proteins is an emerging concept to inhibit the function of undruggable proteins. Protein targets without reliable ligands and/or existing outside the cells where ubiquitin-proteasome systems do not exist, however, are beyond the scope of currently available protein degradation strategies. Here, we disclose photooxygenation catalyst 7 that permeates the blood-brain barrier and selectively and directly degrades an extracellular Alzheimer’s disease–related undruggable protein, amyloid-β protein (Aβ). Key was the identification of a compact but orange color visible light–activatable chemical catalyst whose activity can be switched on/off according to its molecular mobility, thereby ensuring high selectivity for aggregated Aβ. Chemical catalyst–promoted protein degradation can be applied universally for attenuating extracellular amyloids and various pathogenic proteins and is thus a new entry to induced protein degradation strategies.


2021 ◽  
Vol 22 (4) ◽  
pp. 2099
Author(s):  
Nikol Jankovska ◽  
Tomas Olejar ◽  
Radoslav Matej

Alzheimer’s disease (AD) and sporadic Creutzfeldt–Jakob disease (sCJD) are both characterized by extracellular pathologically conformed aggregates of amyloid proteins—amyloid β-protein (Aβ) and prion protein (PrPSc), respectively. To investigate the potential morphological colocalization of Aβ and PrPSc aggregates, we examined the hippocampal regions (archicortex and neocortex) of 20 subjects with confirmed comorbid AD and sCJD using neurohistopathological analyses, immunohistochemical methods, and confocal fluorescent microscopy. Our data showed that extracellular Aβ and PrPSc aggregates tended to be, in most cases, located separately, and “compound” plaques were relatively rare. We observed PrPSc plaque-like structures in the periphery of the non-compact parts of Aβ plaques, as well as in tau protein-positive dystrophic structures. The AD ABC score according to the NIA-Alzheimer’s association guidelines, and prion protein subtype with codon 129 methionine–valine (M/V) polymorphisms in sCJD, while representing key characteristics of these diseases, did not correlate with the morphology of the Aβ/PrPSc co-aggregates. However, our data showed that PrPSc aggregation could dominate during co-aggregation with non-compact Aβ in the periphery of Aβ plaques.


2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Woo Shik Shin ◽  
Jing Di ◽  
Qin Cao ◽  
Binsen Li ◽  
Paul M. Seidler ◽  
...  

An amendment to this paper has been published and can be accessed via the original article.


Sign in / Sign up

Export Citation Format

Share Document